The pharmaceutical company Cedal Nano proudly announces the launch of the chemotherapy drug Etoposide, under the brand name Etopodal®️, for the first time in Iran. Produced in compliance with advanced standards, this medication represents a significant step forward in improving treatment options for cancer patients.

Etopodal®️, with a concentration of 20 mg/ml, is available in 100 mg and 200 mg doses as a ready-to-use injectable solution. It is now accessible to patients under insurance coverage.

At Cedal Nano, we firmly believe that every dose of medication carries new hope for patients and contributes to enhancing their quality of life.

We Made It for All